Anticancer Agent 141 (Compound AE), an antimycin alkaloid, exhibits inhibitory potential against HPV-infected cervical cancer. It impedes HeLa cell proliferation by arresting the cell cycle at the S phase and induces caspase-dependent apoptosis through mitochondrial disruption. This disruption activates the ROS-mediated ubiquitin-dependent proteasome system, leading to the degradation of E6/E7 oncoproteins [1].

Anticancer agent 141 (compound AE) at a concentration of 0.1 μM for 24 hours significantly reduced the levels of p53 and Cyclin D1 in HeLa cells. It inhibited the phosphorylation of PI3K, Akt, and STAT3, without affecting their total protein levels [1]. At 0.4 μM for 24 hours, Anticancer agent 141 mediated the degradation of E6/E7 by increasing the activation of the UPS in HeLa cells [1]. The IC50 values of Anticancer agent 141 for HeLa cells at 24, 48, and 72 hours were 1.35, 0.12, and 0.03 μM, respectively [1].